SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Garcia-Manero, G; Othus, M; Pagel, JM; Radich, JP; Fang, M; Rizzieri, DA; Marcucci, G; Strickland, SA; Litzow, M; Savoie, ML; Medeiros, BC; Sekeres, MA; Lin, TL; Uy, GL; Powell, BL; Kolitz, JE; Larson, RA; Stone, RM; Claxton, DF; Essell, J; Luger, S; Mohan, SR; Moseley, A; Appelbaum, FR; Erba, HP

Published Date

  • December 2, 2016

Published In

Volume / Issue

  • 128 / 22

Published By


  • 9

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Conference Location

  • San Diego, CA

Conference Start Date

  • December 3, 2016

Conference End Date

  • December 6, 2016